CLINICAL ROLE -
Britny Brown, PharmD, BCOP, discusses the importance of the NCCN guidelines in the treatment of metastatic breast cancer (mBC) and explains how the NCCN recommendations for CDK4/6 inhibitors differ for first-line patients.
FDA Grants Inavolisib Priority Review for Treatment of PIK3CA-Mutated Breast Cancer
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
FDA Grants Breakthrough Therapy Designation to Inavolisib for PIK3CA-Mutated Breast Cancer
Pharmacy Focus: Oncology Edition - Breast Cancer Treatments Are Rapidly Expanding
Adiposity in Childhood May Affect the Risk of Developing Breast Cancer in Adulthood
US Preventive Services Task Force Recommends Breast Cancer Screenings Begin at Age 40